← Oncology Approval Tracker

FDA DECISION ·

Tecentriq Hybreza

atezolizumab and hyaluronidase-tqjs · Genentech

FDA approvalNew formulationMultiple solid tumors
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Subcutaneous use for adult indications shared with IV atezolizumab, including specified lung, liver, melanoma and alveolar soft part sarcoma indications.

LAMPGEN ANALYSIS

Why it matters

The formulation adds a subcutaneous route, with a bridging study in previously treated non-small cell lung cancer.

What research teams should watch

Separate IV and subcutaneous orders, and confirm the indication and any combination partners before a route change.

PRIMARY RECORDS

Sources